Pharmos (PARS) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS)

PARS 2.700

+13.6%

Jan 21 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: NeuroInvestment who wrote (1310)	11/23/2004 12:53:00 PM
From: Biomaven	Read Replies (1) of 1386

in fact I am not aware of any drug producing a positive neuroprotectant effect in CABG What about ALXN's complement-inhibiting drug? I don't recall the details, but I do recall them claiming (with some fanfare) effects on some of the tests they administered post-CABG. Don't know if there was any long-term follow-up though. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next